You are Here: LUHS > CBCCOncology Institute > Faculty > Publications

Nancy Zeleznik-Le, PhD

  • Erfurth FE, Popovic R, Grembecka J, Cierpicki T, Theisler C, Xia Z-B, Stuart T, Diaz M, Bushweller JH, Zeleznik-Le NJ. MLL protects CpG clusters from methylation within the Hoxa9 gene, maintaining transcript expression. Proc. Natl Acad Sci USA, in press, 2007.
     

  • Popovic R, Erfurth FE, and Zeleznik-Le NJ. Transcriptional Complexity of the HOXA9 Locus. Blood Cells, Mol Dis., in press, 2007.
     

  • Baron BW, Zeleznik-Le NJ, Baron MJ, Theisler C, Huo D, Krasowski MD, Thirman MJ, Perrella MA, Baron RM, Baron JM. Repression of the programmed cell death-2 (PDCD2) gene by BCL6—implications for the pathogenesis of human B- and T-cell lymphomas. Proc. Natl. Acad. Sci. USA 104:7449-54, 2007.
     

  • Santillan DA, Theisler CM, Ryan AS, Stuart T, Zhou MM, Alkan S, Zeleznik-Le NJ. Bromodomain and Histone acetyltransferase domain specificities control MLL leukemia phenotype. Cancer Res 66: 10032-9, 2006.


  •  
  • Zeleznik-Le, NJ. Leukemia RNAi: harnessing the killer within. Blood 106: 3336-3337, 2005.
     

  • Xia, Z-B, Popovic, R, Chen, J, Theisler, C, Lorenz, T, Santillan, DA, Erfurth, F, Diaz, MO, Zeleznik-Le, NJ. The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression. Proc. Natl Acad Sci USA 102:14028-33, 2005.
     

  • Xia, Z-B, Popovic, R, Chen, J, Theisler, C, Lorenz, T, Santillan, DA, Erfurth, F, Diaz, MO, Zeleznik-Le, NJ. The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression. Proc. Natl Acad Sci USA 102:14028-33, 2005.
     

  • Popovic R, Zeleznik-Le NJ. MLL: How complex does it get? J Cell Biochem. 95(2):234-42, 2005.
     

  • Mujtaba S, He Y, Zeng, L, Yan S, Plotnikova O, Sanchez R, Zeleznik-Le, NJ, Ronai Z, Zhou MM. Structural mechanism of the bromodomain of coactivator CBP in p53 transcriptional activation. Mol. Cell. 13:251-263, 2004.
     

  • MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein. PNAS, 100(14):8342-8347, 2003.
     

  • Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia. The EMBO Journal, 19:4655-4664, 2000.
     

  • MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16) (q23;p13.3). Proc Natl Acad Sci, 94:8732-8737, 1997.
     

  • 11q23 translocations split the “AT-hook” cruciform DNA-binding region and the transcriptional repression domain from the activation domain of the mixed-lineage leukemia (MLL) gene. Proc Natl Acad Sci, 91:10610-10614, 1994.

©1995-2005 Loyola University Health System. All rights reserved.
Disclaimer
| Terms and Conditions | Privacy Policy

Webmaster: Lorelei Hacholski 

Last reviewed: Nov. 12, 2007